Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (SKB BIO, 06990) announced that all seven resolutions tabled at its 29 June 2026 Annual General Meeting (AGM) were approved by substantial majorities.

Shareholder turnout and voting structure • Voting rights attached to 165.13 million shares—70.81% of the company’s 233.19 million issued shares—were exercised via poll. • No shareholders were required to abstain from voting, and no votes were cast against the first four ordinary resolutions.

Key ordinary-resolution outcomes 1. 2025 Board Report and 2025 audited consolidated financial statements (audited by KPMG) each secured 99.98% support. 2. KPMG was re-appointed auditor for 2026, with pre-tax remuneration capped at RMB2.80 million; 99.98% of votes were in favour. 3. The 2025 profit distribution plan passed with 99.99% approval. 4. A mandate allowing the company to use idle self-owned funds for 2026 wealth-management products received 96.71% support; 3.28% opposed.

Special resolutions • General mandate to issue shares and sell treasury shares: 96.41% approval. • General mandate to repurchase H-shares: 99.98% approval.

Board and meeting compliance All members of the Board—comprising one executive, six non-executive and four independent non-executive directors—attended the AGM in person or via tele-/video-conference. Meeting procedures complied with PRC laws, relevant regulations and the company’s articles of association. Computershare Hong Kong Investor Services Limited and shareholder representatives acted as vote scrutineers.

With the passage of these resolutions, Kelun-Biotech secures continued auditor oversight, confirms its 2025 financial results and dividend plan, and renews financial management flexibility through approved investment, issuance and repurchase authorities.